<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543423</url>
  </required_header>
  <id_info>
    <org_study_id>UC/RH-early phase</org_study_id>
    <nct_id>NCT03543423</nct_id>
  </id_info>
  <brief_title>Studies of the Early Meal Phase in Healthy Individuals - Nutrient Absorption and Gastrointestinal Hormone Secretion</brief_title>
  <official_title>Studier af Den Tidlige Måltidsfase i Raske Individer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate gastrointestinal hormone secretions and nutrient absorption during the early
      meal phase we will recruit 12 healthy young men. They will be equipped with peripheral
      intravenous catheters for frequent blood sampling. Participants will be screened and
      acclimatised to the study situation on visit 1. On visit 2 and 3 participants will in random
      order ingest an oral glucose solution or a standardised liquid mixed meal over 2-3 min.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Anticipated">June 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>12 healthy male individuals will each be studied on two occasions in random order.
oral glucose tolerance test
liquid mixed meal test</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma GIP concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Glucose-dependent insulinotropic polypeptide plasma concentrations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma GLP-1 concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Glucagon-like peptide-1 plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 3-OMG concentrations</measure>
    <time_frame>-10, -2, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30</time_frame>
    <description>Serum 3-OMG concentrations (glucose absorption marker)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-peptide and insulin concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Glucagon-like peptide-1 plasma concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma gastrin concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma gastrin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma CCK concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma cholecystokinin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PP concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma pancreatic polypeptide concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NT concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma Neurotensin concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma glucagon concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma glucagon concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum 3-OMG concentrations</measure>
    <time_frame>-40, -20, -18, -16, -14, -12, -10, -8, -6, -4, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Serum 3-OMG concentrations (glucose absorption marker)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma acetaminophen</measure>
    <time_frame>-10, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma acetaminophen (as a measure of gastric emptying)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma amino acids</measure>
    <time_frame>-10, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma amino acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma bile acids</measure>
    <time_frame>-10, -2, 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 30 min</time_frame>
    <description>Plasma bile acids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: oral glucose tolerance test (75 gram glucose supplemented with 5g 3-OMG and 1g paracetamol) ingested over 2 min.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liquid mixed meal test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Standardised liquid mixed meal (supplemented with 1g paracetamol) ingested over 2min</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oral glucose tolerance test</intervention_name>
    <description>Oral glucose tolerance test will be carried out with a glucose solution made up of 75g glucose dissolved in 300mL. To the glucose solution will be added 5g 3-OMG and 1g paracetamol 5g 3-OMG</description>
    <arm_group_label>Oral glucose tolerance test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid mixed meal test</intervention_name>
    <description>A standardised liquid mixed meal test will be carried out using a standard liquid mixed meal (fresubin drink supplemented with 1g paracetamol).</description>
    <arm_group_label>Liquid mixed meal test</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 40years

          -  Male

          -  Normal Haemoglobin concentration

          -  Informed consent

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Family history of diabetes mellitus

          -  intestinal disease (for example inflammatory bowel disease or malabsorption)

          -  Family history of inflammatory bowel disease

          -  Previous intestinal resection (except uncomplicated appendicectomy)

          -  Body mass index (BMI) &gt; 25 kg/m2

          -  Tobacco use

          -  kidney disease (se-creatinine&gt; 130 µM and/or albuminuria)

          -  liver disease (ALAT and/or ASAT &gt;2 × above normal range)

          -  Heart disease

          -  Treatment with drugs

          -  History of constipation

          -  Conditions with delayed or accelerated gastric emptying

          -  Latex or other allergies

          -  Bleeding diathesis
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens J Holst, DMSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Biomedical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Simon Veedfald, MD</last_name>
    <phone>+45 41102595</phone>
    <email>veedfald@sund.ku.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jens J Holst, DMSCI</last_name>
    <email>jjholst@sund.ku.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Gastrointestinal Surgery, Righospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>Capital</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Bo Svendsen, DMSci</last_name>
      <email>lars.bo.svendsen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Simon Veedfald, MD</last_name>
      <phone>+4541102595</phone>
      <email>Simon.veedfald@regionh.dk</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Veedfald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jens J Holst, DMsci</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Bo Svendsen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Copenhagen</investigator_affiliation>
    <investigator_full_name>Simon Veedfald</investigator_full_name>
    <investigator_title>Post doc</investigator_title>
  </responsible_party>
  <keyword>Gut hormone secretion</keyword>
  <keyword>Glucose absorption</keyword>
  <keyword>early meal phase</keyword>
  <keyword>Insulin and glucagon secretion</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

